Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05952453 · ClinicalTrials.gov registry record · Phase 2

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

A Phase 2 study of Ovarian Cancer, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT05952453: Recruiting Phase 2 study of Ovarian Cancer, sponsored by University of Alabama at Birmingham.

NCT05952453 is a Phase 2 study of Ovarian Cancer that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 20 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05952453, a Phase 2 study of Ovarian Cancer, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

this is a trial evaluating three chemotherapy agents in patients with newly diagnosed ovarian cancer patients that are Stage III or Stage IV prior to surgery to remove the tumor. After surgery there will be additional chemotherapy given.

Primary Outcome

Progression free survival at 36 month according to Response Evaluation Criteria in Solid tumors RECIST 1.1

Conditions Studied

Ovarian Cancer

Interventions

  • DRUG Carboplatin
  • DRUG olaparibp, embro

Study Locations (1)

Alabama

  • O'Neal Comprehensive Cancer Center at UAB - Birmingham

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-02-17
Est. Completion 2030-12-30
Phase Phase 2
University of Alabama at Birmingham

1,160 total trials

What NCT05952453 shows while recruiting

NCT05952453 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Carboplatin is the first listed.

NCT05952453 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT05952453 about?

NCT05952453 is a clinical study titled "Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro". this is a trial evaluating three chemotherapy agents in patients with newly diagnosed ovarian cancer patients that are Stage III or Stage IV prior to surgery to remove the tumor. After surgery there will be additional chemotherapy given.

What is the current status of trial NCT05952453?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-02-17. Estimated completion is 2030-12-30.

What conditions does trial NCT05952453 study?

This clinical trial studies the following conditions: Ovarian Cancer.

What interventions are being tested in trial NCT05952453?

The interventions under investigation include: Carboplatin (DRUG), olaparibp, embro (DRUG).

Who is sponsoring clinical trial NCT05952453?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05952453 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05952453's enrollment target sits among peer trials

20 284th of 322 higher than 34 of 322 other Ovarian Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05952453

Source: ClinicalTrials.gov NCT05952453, the US trial registry maintained by the National Library of Medicine. NCT05952453 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.